Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 30769 matches for

Researchers have developed a vaccine that blocks the effects of the main cause of pain in osteoarthritis (OA) - nerve growth factor (NGF) - in mice.

Unrecognizable Senior old woman walking alone with walker on the city street, elderly and disability concept © Shutterstock

Research groups

About us

Trials

Available studentship projects

Applications for this project are now closed.

UCB-Translational Pharmacology Scholarship

Applications for this project are now closed.

Oxford Trauma

OPEN ARMS

Study with us

Events

SITU

Jobs

Trials in closure

Trials in follow up

Trials under analysis

Trials open to recruitment

Trials in set-up

Themes

OCTRU runs trials across multiple areas of medicine. Within OCTRU there are five core therapeutic areas of expertise, although trials are also undertaken outside of these areas and groups.

Our studies

Lymphocyte Antigen Receptor Signaling Workshop

Information Security Policy

Load More

Meet the Kennedy team

  • Tonia Vincent
    Tonia Vincent

    Professor of Musculoskeletal Biology & Honorary rheumatologist

Read the paper

Active immunization targeting Nerve Growth Factor attenuates chronic pain behavior in murine osteoarthritis

Annals of Rheumatic Disease, 12 March 2019. doi: 10.1136/annrheumdis-2018-214489

Full paper

In collaboration with

Supported by

Versus Arthritis logo

Find out more about

Similar stories